Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL
Saved in:
| Published in: | Rare Cancers and Therapy |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL
- In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses
- Health Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2
- Analysis of Treatment Patterns for Mucosal Melanoma Using Real‐World Data in the SEER‐Medicare–Linked Database
- Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study
- Real‐World Survival Over 25 Years in Extensive‐Stage Small‐Cell Lung Cancer: The Impact of Immune Checkpoint Inhibitors
- EXPRESSION OF CONCERN: A Newly Identified 45‐kDa JAK2 Variant with an Altered Kinase Domain Structure Represents a Novel Mode of JAK2 Kinase Inhibitor Resistance